The phrase algae desaturase enzyme conversion efficiency versus human sounds like a niche biochemistry search. It is. But it points to one of the most interesting pieces of the omega-3 story: a tiny marine microalga carries an enzyme that is extraordinarily good at recognizing the plant omega-3 fatty acid ALA and pushing it into the pathway that leads to longer-chain omega-3s.
The organism is Micromonas pusilla, a microscopic marine alga. The enzyme is called MpFADS6, a delta-6 desaturase. In experimental research, this enzyme showed roughly 63% conversion of ALA, compared with much lower conversion rates typically reported for humans trying to turn dietary ALA into longer-chain omega-3 fatty acids.
That sounds like a simple eight-times comparison. It is not quite that simple.
The 63% figure describes the activity of a specific algal enzyme at a particular step in the fatty-acid pathway. Human estimates generally describe the outcome of a much larger, whole-body metabolic pathway, often involving several enzymes and competing fates for ALA. So the comparison is best understood as a striking illustration of enzyme specialization, not as a literal human-versus-algae laboratory race under identical conditions.
That distinction makes the finding more fascinating, not less.
It helps explain why marine microalgae are so important to the global omega-3 story, why fish can contain EPA and DHA without being the original producers, and why the human body is relatively inefficient at building those longer-chain fatty acids from ALA.
The basic idea is surprisingly simple:
Some algae are exceptionally good at starting the conversion. Humans are comparatively reluctant to finish it.
Here is what is happening at the molecular level.
What Does the Algae Desaturase Enzyme Actually Do?
The key enzyme is delta-6 desaturase, commonly referred to as FADS6 in many microbial and non-mammalian studies.
Its job is to introduce another double bond into a polyunsaturated fatty acid. In the omega-3 pathway, that means taking alpha-linolenic acid, or ALA, and converting it into stearidonic acid, or SDA.
The pathway begins like this:
ALA → SDA → longer-chain intermediates → EPA → DHA
ALA contains 18 carbon atoms and three double bonds, so it is often written as 18:3n-3.
SDA contains 18 carbon atoms and four double bonds, or 18:4n-3.
That extra double bond matters because it moves the fatty acid one crucial step deeper into the biochemical route toward EPA.
This is the part that often gets lost in simplified explanations of omega-3 metabolism.
The Micromonas enzyme does not take one molecule of ALA and instantly produce EPA or DHA. The reported ~63% conversion refers to the enzyme's ability to perform its particular first desaturation step, converting ALA toward SDA.
So why does that matter so much?
Because in any multi-step metabolic pathway, a slow first gate can constrain everything downstream.
Think of the pathway as a series of doors.
ALA is outside Door One.
SDA is inside Door One.
EPA and DHA are several doors farther down the hall.
If an organism has an enzyme that opens Door One extremely efficiently, it has a major advantage in moving ALA into the rest of the omega-3 pathway.
That is exactly what makes the Micromonas algae FADS6 enzyme so interesting.
The 63% Number: What It Really Means
The headline number comes from research comparing the substrate preferences and conversion efficiencies of different delta-6 desaturases.
The Micromonas pusilla enzyme showed a strong preference for ALA over linoleic acid, the major omega-6 precursor.
In the experimental system used to characterize it, the enzyme's reported conversion efficiency was approximately 63% for ALA, compared with about 4.9% for linoleic acid.
That is an enormous preference for the omega-3 substrate.
The important phrase is substrate preference.
An enzyme does not simply work on everything equally. Its structure determines which molecules fit well, which are recognized efficiently, and which reactions proceed readily.
MpFADS6 appears to be unusually well adapted to recognizing an omega-3 substrate.
That gives us a more useful interpretation of the 63% figure:
The enzyme is not merely capable of processing ALA. It strongly favors ALA.
Later research on the enzyme reported an ALA conversion rate in the mid-60% range under experimental conditions, consistent with the original finding.
That consistency is important because it shows that the unusual ALA preference was not simply a one-off observation.
Why the number is sometimes described as “eight times” human efficiency
This is where the popular comparison comes from.
Human ALA conversion is generally described as limited. Depending on the study, population, experimental design, and endpoint, estimates vary. Commonly cited values put conversion from ALA to EPA in the low single digits or around the high single digits, while conversion all the way to DHA is substantially lower.
A frequently cited combined estimate is around 5% to 8% for ALA conversion to EPA and/or DHA, although individual studies report a wider range.
Take the upper end of that commonly cited range:
63 ÷ 8 = 7.875
That is approximately eight times.
But this calculation should not be interpreted as “the algal enzyme is literally eight times faster than the human enzyme.”
It compares two different kinds of measurements.
The algal number describes conversion at a specific enzyme step.
The human number often describes conversion through a multi-step metabolic pathway.
So the better headline is:
A specialized marine algal desaturase can convert ALA at a rate dramatically higher than the low overall human conversion of ALA into longer-chain omega-3s.
That is scientifically more accurate, while still preserving the remarkable comparison.
Why Human ALA Conversion Is So Much Less Efficient
Humans do have a delta-6 desaturase.
In humans, the relevant enzyme is generally called FADS2 rather than MpFADS6.
FADS2 performs the same basic ALA-to-SDA reaction:
ALA → SDA
From there, the human body relies on additional elongation and desaturation reactions to build EPA and eventually DHA.
So humans are not missing the machinery.
The problem is efficiency.
The human omega-3 pathway is constrained by several factors at once.
1. The enzymes have multiple jobs
Human fatty-acid metabolism is not built exclusively around producing EPA and DHA.
FADS2 participates in the metabolism of both omega-3 and omega-6 fatty acids.
That means ALA is not entering a private production line reserved for omega-3 synthesis.
Its pathway overlaps with the metabolism of other polyunsaturated fatty acids, particularly linoleic acid and its downstream products.
This creates competition for enzymatic activity.
An enzyme that handles multiple substrates has a different job from an enzyme that evolved in an organism where a particular substrate is strongly favored.
MpFADS6 is especially interesting because it appears to have a pronounced preference for ALA.
2. Human ALA has other metabolic destinations
Not all dietary ALA is waiting around to become EPA or DHA.
A meaningful fraction can be oxidized for energy or incorporated into other lipid pools.
In human tracer studies, a substantial portion of ALA can be rapidly catabolized rather than converted into long-chain omega-3s.
That means the molecule is competing with the body's broader energy and lipid requirements.
The amount that actually reaches the EPA/DHA pathway is therefore only a fraction of the ALA consumed.
3. The pathway requires multiple steps
The first desaturation is only the beginning.
After ALA becomes SDA, additional enzymes must elongate and desaturate the fatty acid.
A simplified version of the omega-3 biosynthetic route looks like this:
ALA
↓ delta-6 desaturase
SDA
↓ elongation
20:4n-3
↓ delta-5 desaturase
EPA
↓ elongation and additional reactions
DHA
Every step presents another opportunity for metabolic bottlenecks.
This is a major reason why saying “the body converts ALA into DHA” can be technically true while still being misleading.
The body can perform the conversion.
It just does not do it with anything close to the efficiency seen in certain specialized microbial systems.
The Real Difference Is Substrate Preference
The most fascinating part of the Micromonas discovery is not simply that its enzyme works.
It is what the enzyme prefers.
Fatty-acid desaturases interact with specific substrates in highly structured ways. Small changes in the protein can affect how well it recognizes one fatty acid compared with another.
Research comparing the Micromonas enzyme with a delta-6 desaturase from another organism found that regions between the enzyme's conserved histidine boxes played an important role in substrate preference.
Specific amino-acid substitutions altered how the enzyme recognized its preferred substrate.
In other words, the enzyme's sequence helps determine whether its molecular “grip” is better suited to ALA or to another fatty acid.
This gives us a useful lesson in biochemistry:
Enzyme efficiency is not just about having the right enzyme. It is about having an enzyme whose structure is exceptionally well matched to the molecule you want to process.
Micromonas appears to have precisely that kind of match.
Why Would Marine Microalgae Be So Good at Making Omega-3s?
Now we reach the bigger evolutionary story.
Marine microalgae sit near the base of many aquatic food webs. Numerous organisms in marine ecosystems ultimately acquire EPA and DHA by consuming algae directly or by eating organisms that consumed algae.
That is why the familiar image of “omega-3 comes from fish” is incomplete.
Fish can be important dietary sources of EPA and DHA, but they are not necessarily the original manufacturers of those fatty acids.
Microalgae are among the primary producers of long-chain marine omega-3s.
The fish are, in many cases, downstream customers.
This is especially important for understanding vegan omega-3 sources.
When an algal oil supplement provides EPA or DHA directly, there is no need for the consumer to convert ALA through the human pathway first.
The omega-3 is already present in its long-chain form.
That bypasses the bottleneck.
Algae Versus Humans: The Conversion Efficiency Comparison
Here is the simplest way to think about the comparison.
| Feature | Micromonas pusilla enzyme | Human metabolism |
|---|---|---|
| Key enzyme | MpFADS6 | FADS2 |
| Main first-step substrate | Strong preference for ALA | ALA plus other fatty-acid substrates |
| ALA → SDA conversion | Roughly 63% in the documented experimental work | Part of a much less efficient whole-body pathway |
| ALA → EPA | Requires additional downstream steps | Requires additional downstream steps |
| ALA → DHA | Requires many downstream steps | Particularly inefficient |
| Primary limitation | Specific enzyme substrate preference and system conditions | Multiple enzymes, competing substrates and metabolic fates |
| Big takeaway | Specialized omega-3 processing | Limited endogenous conversion |
The comparison is not a controlled race between a single algal enzyme and a single human enzyme.
It is better understood as a comparison of two metabolic strategies.
One is highly specialized.
The other is highly generalist.
And when it comes to turning ALA into long-chain omega-3s, specialization wins.
What Makes Micromonas FADS6 So Unusual?
Many plants and microbes have delta-6 desaturases, but they do not all behave the same way.
Some prefer linoleic acid, or LA, which belongs to the omega-6 family.
Others show stronger activity toward ALA, the omega-3 precursor.
This distinction matters because the same basic enzyme class can lead an organism's lipid metabolism in very different directions.
A delta-6 desaturase that favors LA tends to feed the omega-6 pathway.
A delta-6 desaturase that favors ALA can push more carbon toward the omega-3 pathway.
Micromonas is remarkable because its enzyme has an unusually strong omega-3 preference.
The documented comparison found approximately:
LA conversion: 4.9%
ALA conversion: 63%
That is more than a difference in efficiency.
It is a difference in preference.
The enzyme is strongly biased toward the omega-3 substrate.
This helps explain why the organism became such an attractive source of genetic machinery for biotechnology research.
Researchers Used the Enzyme to Improve Omega-3 Production in Other Organisms
The discovery did not remain a curiosity.
Researchers used the Micromonas delta-6 desaturase in other biological systems to test whether its strong ALA preference could be transferred.
In one major example, scientists introduced the Micromonas enzyme into plants as part of an engineered pathway designed to produce long-chain omega-3 fatty acids.
The enzyme increased production of omega-3 intermediates and helped demonstrate that it could function effectively outside its original algal environment.
Later work used the same gene in a fungal production system to push metabolism toward EPA.
This is one of the most compelling demonstrations of superior conversion efficiency algae.
The enzyme's value was not merely that Micromonas possessed it.
Its value was that researchers could move the enzyme into another organism and still observe its useful omega-3 preference.
That tells us the property is embedded in the enzyme's molecular structure.
The “Algae Is the Original Source” Story Gets More Interesting Here
You've probably heard the simplified version:
Fish contain omega-3s because they eat algae.
That is broadly useful, but it leaves out the most interesting part.
Algae are not simply passive nutrients at the bottom of the marine food chain.
Certain microalgae possess highly specialized biochemical systems for making and modifying polyunsaturated fatty acids.
The Micromonas example gives that story a molecular explanation.
Instead of saying:
“Algae make omega-3s really well.”
We can say:
A marine microalga contains a delta-6 desaturase whose substrate preference strongly favors ALA, allowing the organism to push an unusually large fraction of the available substrate through the first committed step toward omega-3 long-chain synthesis.
That is a much more satisfying explanation.
The advantage exists at the enzyme level.
Why Humans Didn't Evolve to Do the Same Thing
It is tempting to frame this as though human metabolism is simply poorly designed.
That misses the point of evolution.
Human metabolism evolved to perform many jobs simultaneously.
We need pathways for energy production, membrane construction, storage, signaling molecules and countless other processes.
An enzyme does not exist merely to maximize one dietary conversion.
The fact that humans convert ALA inefficiently does not necessarily mean the pathway is “broken.”
It means the pathway is regulated within a much larger metabolic system.
Marine microalgae live under completely different ecological pressures.
Their lipid metabolism is shaped by their own cellular requirements and their marine environment.
Different organisms have different biochemical priorities.
Different priorities produce different enzymes.
That is why comparative biochemistry is so useful.
A molecule does not perform a reaction “well” or “poorly” in isolation.
It performs according to the structure and biological context of the system that evolved to use it.
Does Eating More ALA Solve the Problem?
This is one of the most common questions around plant-based omega-3 nutrition.
The answer is more nuanced than simply saying yes or no.
Foods such as flaxseed, chia seeds, hemp seeds and walnuts can provide ALA. ALA is an essential omega-3 fatty acid and an important component of a plant-forward diet.
But increasing ALA intake does not automatically produce a proportional increase in EPA and DHA.
That is because the conversion pathway remains limited.
Imagine a factory that receives 100 units of raw material but has a narrow processing bottleneck.
Doubling the raw material does not necessarily double finished-product output.
Some of the additional material may simply be stored, redirected or used elsewhere.
That is essentially the issue with ALA conversion.
For someone searching, “Why doesn't eating more flaxseed guarantee more EPA and DHA?” the biochemical answer is straightforward:
Because the human ALA-to-long-chain-omega-3 pathway is limited by enzyme activity and by the fact that ALA has other metabolic destinations.
This is also why direct dietary sources of EPA and DHA are metabolically different from eating ALA and waiting for the body to manufacture them.
Does Algal EPA or DHA Have to Be Converted by Humans?
No.
This distinction is particularly important when comparing ALA-rich plant foods with EPA- or DHA-containing algal oil.
ALA is a precursor.
EPA and DHA are already long-chain omega-3 fatty acids.
When EPA or DHA is consumed directly, the body does not need to build those molecules from ALA first.
That means an algal source of EPA or DHA can bypass the conversion bottleneck that makes ALA-to-long-chain omega-3 metabolism relatively inefficient.
This is one reason marine microalgae are so interesting in nutrition research and in plant-based food systems.
They offer a way to obtain long-chain omega-3s directly from a non-animal source.
The biochemical route is different.
A Practical Way to Read Omega-3 Nutrition Labels
A simple label-reading habit can make this whole topic much easier.
When looking at an omega-3 food or supplement, identify which molecules it actually provides.
ALA
This is the plant-derived essential omega-3 precursor.
Common food sources include flaxseed, chia, walnuts and certain plant oils.
ALA is valuable, but it is not EPA or DHA.
EPA
This is a long-chain omega-3 with 20 carbon atoms.
It can be produced from ALA through a series of metabolic steps, but human conversion is limited.
DHA
DHA is an even longer-chain omega-3 with 22 carbon atoms.
Conversion from ALA to DHA is especially limited in humans.
Algal EPA or DHA
This means the long-chain omega-3 is already present in the source.
The consumer does not have to rely on ALA conversion to obtain that molecule.
For readers interested in plant-based nutrition, this distinction is more useful than simply counting “total omega-3” on a label.
Two products can both contain omega-3 fatty acids while providing very different forms of them.
What This Means for a Plant-Based Lifestyle
There is a larger philosophical lesson here too.
Plant-based living is often discussed as though every nutritional question can be reduced to one simple swap.
Biochemistry is rarely that neat.
Different organisms solve nutritional problems in different ways. Plants, algae, fungi, animals and humans each have distinctive metabolic machinery.
The clever approach is to understand those differences rather than assume that every nutrient follows the same path through every organism.
That principle fits naturally with the broader values behind The Dharma Store, where plant-based living, mindfulness and compassion are part of a wider ethical lifestyle. For people who like expressing those values through what they wear, Vegan T-Shirts provide another simple way to make the philosophy visible.
The science itself remains the interesting part:
Algae do not make omega-3s “magically.” They make them using enzymes with exceptionally useful biochemical preferences.
Why the Enzyme's Specificity Matters More Than the Alga's Size
Micromonas pusilla is tiny.
Extremely tiny.
It is a microscopic marine green alga measured in micrometers, yet the molecular machinery inside a single cell can perform chemistry that has enormous implications for biotechnology and nutrition.
This is a useful reminder that biological importance is not related to physical size.
A microscopic organism can contain a protein that becomes valuable to scientists precisely because its molecular structure solves a problem that larger organisms handle less efficiently.
In this case, the problem is substrate selection.
The enzyme recognizes ALA particularly well and directs it into the omega-3 pathway.
That is why marine microalgae desaturase research is so valuable.
Scientists are not simply studying algae because algae are nutritious.
They are studying algae because algae contain molecular tools that can perform chemistry in ways that may be difficult to reproduce using conventional plant or animal enzymes.
What Did Researchers Learn From Comparing Algal and Other Desaturases?
One of the most useful findings from the comparative work was that substrate preference could be traced to specific parts of the enzyme.
Scientists compared different delta-6 desaturases and divided the proteins into regions to determine which sections influenced substrate recognition.
The results pointed toward sequences located between two conserved histidine boxes.
Further experiments identified particular amino-acid positions that altered substrate recognition when changed.
That means the enzyme's preference is not an abstract property.
It comes from physical molecular details.
The protein effectively has a chemical personality.
One version says, in molecular terms, “ALA fits here very well.”
Another version may be far more comfortable with linoleic acid.
This is one reason comparative enzyme efficiency documented in laboratory research can be so valuable.
By comparing related enzymes from different organisms, researchers can identify the molecular features responsible for useful traits.
Could Humans Be Engineered to Convert ALA Like Micromonas?
This is where the research becomes particularly exciting, but also where caution matters.
Scientists can transfer genes encoding desaturases into other organisms.
Experimental systems have demonstrated that the Micromonas enzyme can function in plants and fungi and can alter their fatty-acid production.
That does not mean humans can or should simply be engineered to express the same enzyme.
Human metabolism is vastly more complicated.
The enzyme would need to work in the right cellular compartment, interact with the correct lipid substrates, receive the appropriate metabolic inputs and fit into a pathway containing all the required downstream enzymes.
An isolated enzyme is not an entire metabolic system.
This is a crucial distinction when interpreting biotechnology research.
Researchers can demonstrate that an enzyme has superior substrate preference without implying that the same enzyme could be dropped into a human cell and produce the same outcome.
The Biggest Scientific Caveat: 63% Is Not a 63% Human Conversion Rate
This deserves its own section because it is the easiest detail to exaggerate.
The documented 63% figure should not be interpreted as:
“63% of every gram of ALA a person eats could become EPA and DHA if humans had the algae enzyme.”
That conclusion does not follow from the research.
The 63% figure relates to the conversion activity of MpFADS6 at the specific delta-6 desaturation step.
The human conversion figures typically discussed in nutrition literature refer to downstream production of longer-chain omega-3s in whole-body metabolism.
Those are different measurements.
The scientifically responsible comparison is:
Micromonas has an exceptionally efficient ALA-preferring first-step desaturase, while humans have a tightly limited multi-step pathway for converting ALA into EPA and DHA.
That is the real story.
And it is plenty impressive without stretching the numbers.
Why the First Step Can Matter So Much
Metabolic pathways often behave like chains.
A pathway can have many enzymes, but the output may depend disproportionately on one slow or highly regulated step.
Delta-6 desaturation is a major gateway in the traditional ALA-to-EPA pathway.
Once ALA becomes SDA, the molecule has crossed an important biochemical threshold.
The structural changes needed for subsequent reactions become possible.
This is why a highly ALA-preferring delta-6 desaturase can have an outsized impact.
It does not have to manufacture EPA by itself.
It simply has to make the first conversion much easier.
The downstream enzymes then have a better supply of the appropriate intermediate.
This is also why researchers were able to improve omega-3 production in engineered organisms by introducing the Micromonas desaturase.
The enzyme was effectively improving the flow into the pathway.
Why This Matters for the Future of Vegan Omega-3s
The practical implications go beyond one microscopic alga.
For years, marine omega-3 discussions often revolved around fish oil.
But the underlying biology points much closer to the source.
Microalgae can synthesize the long-chain omega-3s found further up the marine food chain, and scientists can study the molecular machinery that makes this possible.
That opens the door to production systems that use algae directly rather than relying on fish as an intermediate.
It also gives researchers a library of naturally occurring enzymes that can potentially be used in biotechnology.
The Micromonas example is especially valuable because it demonstrates something specific:
An algal enzyme can be strongly biased toward an omega-3 precursor and can transfer that biochemical preference into other experimental systems.
That is a much more powerful concept than simply saying “algae contains omega-3.”
Common Questions About Algae Desaturase Enzyme Conversion Efficiency Versus Human
What is the Micromonas FADS6 enzyme?
Micromonas FADS6, or MpFADS6, is a delta-6 desaturase from the marine microalga Micromonas pusilla. It catalyzes the first major desaturation step that moves ALA toward longer-chain omega-3 fatty acids by converting ALA into stearidonic acid.
Its standout characteristic is its strong preference for ALA over the omega-6 fatty acid linoleic acid.
Is the Micromonas enzyme really 63% efficient?
Experimental research reported approximately 63% conversion of ALA by MpFADS6 under the conditions used to characterize the enzyme. A later comparative study reported a similar ALA conversion rate in the mid-60% range.
The number describes the enzyme's activity at a particular metabolic step. It does not mean 63% of dietary ALA automatically becomes EPA or DHA in a human body.
Why is ALA conversion so low in humans?
Human conversion is limited because the pathway involves multiple enzymes and competing metabolic demands. Human FADS2 must process more than one substrate, ALA can be diverted into other metabolic pathways, and additional elongation and desaturation reactions are required before EPA or DHA can be produced.
Conversion to DHA is particularly limited.
Is human FADS2 the same thing as algal FADS6?
They perform a related delta-6 desaturase function, but the naming convention differs between organisms. Human FADS2 is the primary human delta-6 desaturase associated with the ALA-to-SDA step, while MpFADS6 refers to the corresponding enzyme characterized from Micromonas pusilla.
They are related in biochemical function, but they are not identical proteins with identical substrate preferences.
Does eating ALA give you EPA and DHA?
The human body can convert some ALA into EPA and then into DHA, but the conversion is limited and varies among individuals and experimental conditions.
That means ALA-rich foods and direct sources of EPA or DHA should not be treated as metabolically identical.
Why are algae important to the omega-3 food chain?
Marine microalgae are primary producers of important omega-3 fatty acids in aquatic ecosystems. Other organisms consume them, and omega-3s can move through the food web.
This helps explain why fish can be rich in EPA and DHA even though the ultimate source of those fatty acids may be microscopic marine organisms.
What to Remember About the Micromonas Discovery
The most useful takeaway is not simply a single percentage.
It is the concept behind the percentage.
A tiny marine alga evolved an enzyme with an unusually strong preference for ALA.
That enzyme, MpFADS6, can convert ALA to the immediate omega-3 pathway intermediate SDA with roughly 63% efficiency under the reported experimental conditions.
Human metabolism is considerably less efficient at moving ALA through to long-chain omega-3s, especially when the entire multi-step pathway is considered.
That difference helps explain why the body can consume ALA without producing large amounts of EPA and DHA.
It also helps explain why marine microalgae are such an important part of the omega-3 story.
And perhaps most importantly, it changes the way we should think about the phrase “algae is the original source.”
The interesting story is not merely that algae contain omega-3s.
The deeper story is that algae possess specialized molecular machinery capable of processing fatty-acid precursors with a degree of substrate preference that human metabolism does not match.
That is the real reason this little organism deserves so much attention.
The next time you see a discussion about plant-based omega-3s, ALA conversion or why humans struggle to produce enough long-chain omega-3s from precursors, think smaller.
Think microscopic.
Think about a single enzyme inside Micromonas pusilla that recognizes ALA and says, chemically speaking:
This is the substrate I was built to use.
The information in this article is for educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding dietary or health concerns.